New radiation boost aims to fight pancreatic cancer

NCT ID NCT06453486

Recruiting now Disease control Sponsor: University Health Network, Toronto Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This phase 2 trial is testing whether high-dose radiation therapy, given after initial chemotherapy, can improve outcomes for people with locally advanced pancreatic cancer. About 43 participants whose tumors responded to chemotherapy will receive targeted radiation. Researchers will track overall survival and quality of life to see if this approach is effective.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: high-dose radiation therapy
What this could lead to: If successful, this approach could offer a more effective way to control locally advanced pancreatic cancer, potentially extending survival and improving quality of life.
What could go wrong: This is a small, early-phase trial with only 43 participants. The treatment may not work better than standard care, and radiation can cause side effects like fatigue or digestive issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED PANCREATIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pancreatic adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LOCALLY ADVANCED PANCREATIC ADENOCARCINOMA

Contacts and locations

Locations

McGill University Health Centre
RECRUITING

Montreal, Quebec, H4A 3J1, Canada
Princess Margaret Cancer Centre
RECRUITING

Toronto, Ontario, M5G 2M9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.